Abstract
Conventional suppositories of tolmetin sodium were prepared by using two different types of Witepsol as an oily base and two different ratios of polyethylene glycol 400: polyethylene glycol 4000 as an water-soluble base. In addition, sustained- release suppositories were prepared by adding Eudragit L-100 ta the suppositories. The effects of the suppository base and the ratios of the polyethylene glycol 400: polyethylene glycols 4000 on the in vitro release characteristics were investigated. The release rate of tolmetin sodium from the conventional suppositories prepared with polyethylene glycol was slower than the other suppositories prepared with Witepsol. All of the suppositories with Eudragit L-100 showed slow-release profiles and the drug release rates clearly depended on the Eudragit L-100 content. When dissolution results were evaluated kinetically, zero order kinetic was observed with the sustained- release suppositories of tolmetin sodium prepared with polyethyleneglycol 400: polyethyleneglycol 4000 by adding Eudragit L-100.
Highlights
Conventional suppositories of tolmetin sodium were prepared by using two different types of Witepsol as an oily base and two different ratios of polyethylene glycol 400: polyethylene glycol 4 0 0 0 as an water-soluble base
The various types of Witepsol and polyethylene glycol (PEG) are commonly used as suppository bases (1 0- 14)
Eudragit L-100 was added to melted suppository base and stirred until homogeneous firsions were formed
Summary
Conventional suppositories of tolmetin sodium were prepared by using two different types of Witepsol as an oily base and two different ratios of polyethylene glycol 400: polyethylene glycol 4 0 0 0 as an water-soluble base. Sustained- release suppositories were prepared by adding Eudragit L-100 ta the suppositories. When dissolution results were evaluated kinetically, zero order kinetic was observed with the sustained- release suppositories of tolmetin sodium prepared with polyethyleneglycol 4 0 0 : polyethyleneglycol 4 0 0 0 by adding Eudragit L- 100. The most &frequent adverse effects are gastrointestinal and include, in descending order of frequency, epigastric or abdominal pain, nausea, vomiting [6] It is almost completely absorbed fiom the gastro-intestinal tract. There are various studies about sustained- release suppositories, so we try to prepare sustainedrelease suppositories of tolmetin sodium by using Eudragit L-100. Eudragit L-100, an anionic polymer, synthesised from methacrylic acid and methacrylic acid methyl ester, provides sustainedrelease effects in suppository [9]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
